Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

Association between CCND1 and XPC polymorphisms and bladder cancer risk: a meta-analysis based on 15 case–control studies

verfasst von: Yifei Wang, Zongping Li, Naibo Liu, Guan Zhang

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Perturbations in cell cycle and DNA repair genes might affect susceptibility to cancer. The aim of this meta-analysis is to generate large-scale evidence to determine the degree to which common Cyclin D1 (CCND1) G870A (dbSNP: rs603965) and xeroderma pigmentosum group C (XPC) Ala499Val (dbSNP: rs2228000) polymorphisms are associated with susceptibility to bladder cancer. The electronic databases PubMed, Embase, Web of Science, and CNKI were searched for relevant studies (with an upper date limit of July 25, 2013). The principal outcome measure for evaluating the strength of association was crude odds ratios (ORs) along with their corresponding confidence intervals (95 %CIs). We found and reviewed nine case–control studies on CCND1 G870A with a total of 6,823 subjects and seven studies on XPC Ala499Val with a total of 7,674 subjects. Our meta-analysis provides evidence that the variant genotype of CCND1 G870A showed a significant association in the occurrence of invasive bladder tumors in former and current smokers. The XPC Ala499Val polymorphism correlated with significant differences between patients and unaffected subjects, but when the groups were stratified by ethnicity, the magnitude of the overall effect was similar only among Caucasian populations. Results from our meta-analysis support the view that the G870A polymorphism may modulate the risk of bladder cancer in conjunction with tobacco smoking and that the Ala499Val polymorphism may contribute to the susceptibility to bladder cancer in Caucasian populations. Our findings, however, warrant larger well-designed studies to investigate the significance of these two polymorphisms as markers of susceptibility to bladder cancer.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Zurück zum Zitat Actinomycin C. Cumulative index to IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. IARC Monogr Eval Carcinog Risk Chem Hum. 1986;39:379–403. Actinomycin C. Cumulative index to IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. IARC Monogr Eval Carcinog Risk Chem Hum. 1986;39:379–403.
3.
Zurück zum Zitat Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007;25:285–95.PubMedCrossRef Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007;25:285–95.PubMedCrossRef
4.
Zurück zum Zitat Vineis P, Talaska G, Malaveille C, Bartsch H, Martone T, et al. DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer. 1996;65:314–6.PubMedCrossRef Vineis P, Talaska G, Malaveille C, Bartsch H, Martone T, et al. DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer. 1996;65:314–6.PubMedCrossRef
5.
Zurück zum Zitat Turesky RJ, Freeman JP, Holland RD, Nestorick DM, Miller DW, et al. Identification of aminobiphenyl derivatives in commercial hair dyes. Chem Res Toxicol. 2003;16:1162–73.PubMedCrossRef Turesky RJ, Freeman JP, Holland RD, Nestorick DM, Miller DW, et al. Identification of aminobiphenyl derivatives in commercial hair dyes. Chem Res Toxicol. 2003;16:1162–73.PubMedCrossRef
6.
Zurück zum Zitat Burger MS, Torino JL, Swaminathan S. DNA damage in human transitional cell carcinoma cells after exposure to the proximate metabolite of the bladder carcinogen 4-aminobiphenyl. Environ Mol Mutagen. 2001;38:1–11.PubMedCrossRef Burger MS, Torino JL, Swaminathan S. DNA damage in human transitional cell carcinoma cells after exposure to the proximate metabolite of the bladder carcinogen 4-aminobiphenyl. Environ Mol Mutagen. 2001;38:1–11.PubMedCrossRef
7.
Zurück zum Zitat Siraki AG, Chan TS, Galati G, Teng S, O'Brien PJ. N-oxidation of aromatic amines by intracellular oxidases. Drug Metab Rev. 2002;34:549–64.PubMedCrossRef Siraki AG, Chan TS, Galati G, Teng S, O'Brien PJ. N-oxidation of aromatic amines by intracellular oxidases. Drug Metab Rev. 2002;34:549–64.PubMedCrossRef
8.
Zurück zum Zitat Wei Q, Spitz MR. The role of DNA repair capacity in susceptibility to lung cancer: a review. Cancer Metastasis Rev. 1997;16:295–307.PubMedCrossRef Wei Q, Spitz MR. The role of DNA repair capacity in susceptibility to lung cancer: a review. Cancer Metastasis Rev. 1997;16:295–307.PubMedCrossRef
9.
Zurück zum Zitat Kaufmann WK, Paules RS. DNA damage and cell cycle checkpoints. FASEB J. 1996;10:238–47.PubMed Kaufmann WK, Paules RS. DNA damage and cell cycle checkpoints. FASEB J. 1996;10:238–47.PubMed
10.
11.
Zurück zum Zitat Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science. 2001;291:1284–9.PubMedCrossRef Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science. 2001;291:1284–9.PubMedCrossRef
12.
Zurück zum Zitat Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22–33.PubMedCrossRef Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22–33.PubMedCrossRef
13.
Zurück zum Zitat Tauchi H, Kobayashi J, Morishima K, van Gent DC, Shiraishi T, et al. Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells. Nature. 2002;420:93–8.PubMedCrossRef Tauchi H, Kobayashi J, Morishima K, van Gent DC, Shiraishi T, et al. Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells. Nature. 2002;420:93–8.PubMedCrossRef
14.
Zurück zum Zitat Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case–control study. Int J Cancer. 2001;92:562–7.PubMedCrossRef Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case–control study. Int J Cancer. 2001;92:562–7.PubMedCrossRef
15.
Zurück zum Zitat Wang M, Gu D, Zhang Z, Zhou J. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health A. 2009;72:698–705.PubMedCrossRef Wang M, Gu D, Zhang Z, Zhou J. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health A. 2009;72:698–705.PubMedCrossRef
16.
Zurück zum Zitat Li C, Jiang Z, Liu X. XPD Lys(751)Gln and Asp (312)Asn polymorphisms and bladder cancer risk: a meta-analysis. Mol Biol Rep. 2010;37:301–9.PubMedCrossRef Li C, Jiang Z, Liu X. XPD Lys(751)Gln and Asp (312)Asn polymorphisms and bladder cancer risk: a meta-analysis. Mol Biol Rep. 2010;37:301–9.PubMedCrossRef
17.
Zurück zum Zitat Sun H, Qiao Y, Zhang X, Xu L, Jia X, et al. XRCC3 Thr241Met polymorphism with lung cancer and bladder cancer: a meta-analysis. Cancer Sci. 2010;101:1777–82.PubMedCrossRef Sun H, Qiao Y, Zhang X, Xu L, Jia X, et al. XRCC3 Thr241Met polymorphism with lung cancer and bladder cancer: a meta-analysis. Cancer Sci. 2010;101:1777–82.PubMedCrossRef
18.
Zurück zum Zitat Li F, Li C, Jiang Z, Ma N, Gao X. XRCC3 T241M polymorphism and bladder cancer risk: a meta-analysis. Urology. 2011;77(511):e1–5. Li F, Li C, Jiang Z, Ma N, Gao X. XRCC3 T241M polymorphism and bladder cancer risk: a meta-analysis. Urology. 2011;77(511):e1–5.
19.
Zurück zum Zitat Zhang Y, Wang X, Zhang W, Gong S. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis. Tumour Biol. 2013;34:973–82.PubMedCrossRef Zhang Y, Wang X, Zhang W, Gong S. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis. Tumour Biol. 2013;34:973–82.PubMedCrossRef
20.
Zurück zum Zitat Dou K, Xu Q, Han X. The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis. Diagn Pathol. 2013;8:112.PubMedCentralPubMedCrossRef Dou K, Xu Q, Han X. The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis. Diagn Pathol. 2013;8:112.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Liu C, Yin Q, Li L, Zhuang YZ, Zu X, et al. APE1 Asp148Glu gene polymorphism and bladder cancer risk: a meta-analysis. Mol Biol Rep. 2013;40:171–6.PubMedCrossRef Liu C, Yin Q, Li L, Zhuang YZ, Zu X, et al. APE1 Asp148Glu gene polymorphism and bladder cancer risk: a meta-analysis. Mol Biol Rep. 2013;40:171–6.PubMedCrossRef
22.
Zurück zum Zitat Zhang F, Wu JH, Zhao W, Liu HT. XRCC1 polymorphisms increase bladder cancer risk in Asians: a meta-analysis. Tumour Biol. 2013 Zhang F, Wu JH, Zhao W, Liu HT. XRCC1 polymorphisms increase bladder cancer risk in Asians: a meta-analysis. Tumour Biol. 2013
23.
Zurück zum Zitat Wang C, Sun Y, Han R. XRCC1 genetic polymorphisms and bladder cancer susceptibility: a meta-analysis. Urology. 2008;72:869–72.PubMedCrossRef Wang C, Sun Y, Han R. XRCC1 genetic polymorphisms and bladder cancer susceptibility: a meta-analysis. Urology. 2008;72:869–72.PubMedCrossRef
24.
Zurück zum Zitat Lao T, Gu W, Huang Q. A meta-analysis on XRCC1 R399Q and R194W polymorphisms, smoking and bladder cancer risk. Mutagenesis. 2008;23:523–32.PubMedCrossRef Lao T, Gu W, Huang Q. A meta-analysis on XRCC1 R399Q and R194W polymorphisms, smoking and bladder cancer risk. Mutagenesis. 2008;23:523–32.PubMedCrossRef
25.
Zurück zum Zitat Lee CC, Yamamoto S, Morimura K, Wanibuchi H, Nishisaka N, et al. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer. 1997;79:780–9.PubMedCrossRef Lee CC, Yamamoto S, Morimura K, Wanibuchi H, Nishisaka N, et al. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer. 1997;79:780–9.PubMedCrossRef
26.
Zurück zum Zitat Hosokawa Y, Arnold A. Mechanism of cyclin d1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer. 1998;22:66–71.PubMedCrossRef Hosokawa Y, Arnold A. Mechanism of cyclin d1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer. 1998;22:66–71.PubMedCrossRef
27.
Zurück zum Zitat Zhou P, Jiang W, Weghorst CM, Weinstein IB. Overexpression of cyclin D1 enhances gene amplification. Cancer Res. 1996;56:36–9.PubMed Zhou P, Jiang W, Weghorst CM, Weinstein IB. Overexpression of cyclin D1 enhances gene amplification. Cancer Res. 1996;56:36–9.PubMed
28.
Zurück zum Zitat Sugasawa K, Shimizu Y, Iwai S, Hanaoka F. A molecular mechanism for DNA damage recognition by the xeroderma pigmentosum group C protein complex. DNA Repair (Amst). 2002;1:95–107.CrossRef Sugasawa K, Shimizu Y, Iwai S, Hanaoka F. A molecular mechanism for DNA damage recognition by the xeroderma pigmentosum group C protein complex. DNA Repair (Amst). 2002;1:95–107.CrossRef
29.
Zurück zum Zitat Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23:257–64.PubMedCrossRef Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23:257–64.PubMedCrossRef
30.
Zurück zum Zitat Chung CJ, Huang CJ, Pu YS, Su CT, Huang YK, et al. Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma. Toxicol Appl Pharmacol. 2008;232:203–9.PubMedCrossRef Chung CJ, Huang CJ, Pu YS, Su CT, Huang YK, et al. Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma. Toxicol Appl Pharmacol. 2008;232:203–9.PubMedCrossRef
31.
Zurück zum Zitat Lin HH, Ke HL, Hsiao KH, Tsai CW, Wu WJ, et al. Potential role of CCND1 G870A genotype as a predictor for urothelial carcinoma susceptibility and muscle-invasiveness in Taiwan. Chin J Physiol. 2011;54:196–202.PubMedCrossRef Lin HH, Ke HL, Hsiao KH, Tsai CW, Wu WJ, et al. Potential role of CCND1 G870A genotype as a predictor for urothelial carcinoma susceptibility and muscle-invasiveness in Taiwan. Chin J Physiol. 2011;54:196–202.PubMedCrossRef
32.
Zurück zum Zitat Garcia-Closas M, Malats N, Real FX, Welch R, Kogevinas M, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536–42.PubMedCrossRef Garcia-Closas M, Malats N, Real FX, Welch R, Kogevinas M, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536–42.PubMedCrossRef
33.
Zurück zum Zitat Liu Y, Wang H, Lin T, Wei Q, Zhi Y, et al. Interactions between cigarette smoking and XPC-PAT genetic polymorphism enhance bladder cancer risk. Oncol Rep. 2012;28:337–45.PubMed Liu Y, Wang H, Lin T, Wei Q, Zhi Y, et al. Interactions between cigarette smoking and XPC-PAT genetic polymorphism enhance bladder cancer risk. Oncol Rep. 2012;28:337–45.PubMed
34.
35.
Zurück zum Zitat Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19:251–3.PubMedCrossRef Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19:251–3.PubMedCrossRef
36.
37.
Zurück zum Zitat Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.PubMedCrossRef Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.PubMedCrossRef
38.
Zurück zum Zitat Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28:123–37.PubMedCrossRef Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28:123–37.PubMedCrossRef
39.
Zurück zum Zitat Cortessis VK, Siegmund K, Xue S, Ross RK, Yu MC. A case–control study of cyclin D1 CCND1 870A → G polymorphism and bladder cancer. Carcinogenesis. 2003;24:1645–50.PubMedCrossRef Cortessis VK, Siegmund K, Xue S, Ross RK, Yu MC. A case–control study of cyclin D1 CCND1 870A → G polymorphism and bladder cancer. Carcinogenesis. 2003;24:1645–50.PubMedCrossRef
40.
Zurück zum Zitat Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.PubMedCrossRef Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.PubMedCrossRef
41.
Zurück zum Zitat Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26:1263–71.PubMedCrossRef Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26:1263–71.PubMedCrossRef
42.
Zurück zum Zitat Sak SC, Barrett JH, Paul AB, Bishop DT, Kiltie AE. Comprehensive analysis of 22 XPC polymorphisms and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:2537–41.PubMedCrossRef Sak SC, Barrett JH, Paul AB, Bishop DT, Kiltie AE. Comprehensive analysis of 22 XPC polymorphisms and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:2537–41.PubMedCrossRef
43.
Zurück zum Zitat Wu X, Gu J, Grossman HB, Amos CI, Etzel C, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006;78:464–79.PubMedCentralPubMedCrossRef Wu X, Gu J, Grossman HB, Amos CI, Etzel C, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006;78:464–79.PubMedCentralPubMedCrossRef
44.
Zurück zum Zitat Zhu Y, Lai M, Yang H, Lin J, Huang M, et al. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis. 2007;28:698–703.PubMedCrossRef Zhu Y, Lai M, Yang H, Lin J, Huang M, et al. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis. 2007;28:698–703.PubMedCrossRef
45.
Zurück zum Zitat Ye Y, Yang H, Grossman HB, Dinney C, Wu X, et al. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008;112:2467–74.PubMedCrossRef Ye Y, Yang H, Grossman HB, Dinney C, Wu X, et al. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008;112:2467–74.PubMedCrossRef
46.
Zurück zum Zitat de Verdier PJ, Sanyal S, Bermejo JL, Steineck G, Hemminki K, et al. Genotypes, haplotypes and diplotypes of three XPC polymorphisms in urinary-bladder cancer patients. Mutat Res. 2010;694:39–44.PubMedCrossRef de Verdier PJ, Sanyal S, Bermejo JL, Steineck G, Hemminki K, et al. Genotypes, haplotypes and diplotypes of three XPC polymorphisms in urinary-bladder cancer patients. Mutat Res. 2010;694:39–44.PubMedCrossRef
47.
Zurück zum Zitat Gangwar R, Mittal RD. Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA Cell Biol. 2010;29:349–56.PubMedCrossRef Gangwar R, Mittal RD. Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA Cell Biol. 2010;29:349–56.PubMedCrossRef
48.
Zurück zum Zitat Yuan L, Gu X, Shao J, Wang M, Zhu Q, et al. Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. DNA Cell Biol. 2010;29:611–7.PubMedCrossRef Yuan L, Gu X, Shao J, Wang M, Zhu Q, et al. Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. DNA Cell Biol. 2010;29:611–7.PubMedCrossRef
49.
Zurück zum Zitat Yuan L. Cyclin D1 polymorphism is associated with risk of bladder cancer in China. Nanjing: Nanjing Medical University; 2011. Yuan L. Cyclin D1 polymorphism is associated with risk of bladder cancer in China. Nanjing: Nanjing Medical University; 2011.
50.
Zurück zum Zitat Liu Y. Interactions of XPC gene polymorphism with prostate cancer and bladder cancer risk in China. Chongqing: Third Military Medical University; 2012. Liu Y. Interactions of XPC gene polymorphism with prostate cancer and bladder cancer risk in China. Chongqing: Third Military Medical University; 2012.
51.
Zurück zum Zitat Cohen LM, McCarthy DM, Brown SA, Myers MG. Negative affect combines with smoking outcome expectancies to predict smoking behavior over time. Psychol Addict Behav. 2002;16:91–7.PubMedCrossRef Cohen LM, McCarthy DM, Brown SA, Myers MG. Negative affect combines with smoking outcome expectancies to predict smoking behavior over time. Psychol Addict Behav. 2002;16:91–7.PubMedCrossRef
52.
Zurück zum Zitat Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene–environment interactions. J Clin Oncol. 2000;18:2309–15.PubMed Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene–environment interactions. J Clin Oncol. 2000;18:2309–15.PubMed
53.
Zurück zum Zitat Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.PubMed Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.PubMed
54.
Zurück zum Zitat Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000;89:630–9.PubMedCrossRef Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000;89:630–9.PubMedCrossRef
55.
Zurück zum Zitat Hecht SS. Tobacco smoke carcinogens and breast cancer. Environ Mol Mutagen. 2002;39:119–26.PubMedCrossRef Hecht SS. Tobacco smoke carcinogens and breast cancer. Environ Mol Mutagen. 2002;39:119–26.PubMedCrossRef
Metadaten
Titel
Association between CCND1 and XPC polymorphisms and bladder cancer risk: a meta-analysis based on 15 case–control studies
verfasst von
Yifei Wang
Zongping Li
Naibo Liu
Guan Zhang
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1412-9

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.